Popular Articles

New Drug Targeting Cancer Weakness Shows Great Promise
Scientists at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, working with pharmaceutical company AstraZeneca, have completed a Phase I clinical trial demonstrating the great promise of a completely new type of cancer treatment. The results are announced today in The New England Journal of Medicine.
drugs without prescription
Scientists Shed New Light On Cause Of Inherited Movement Disorder
University of Utah School of Medicine researchers and their colleagues at University of Texas (UT) Southwestern Medical Center have found strong evidence that abnormal calcium signaling in neurons may play an important role in the development of spinocerebellar ataxia type 2 (SCA2), a disorder causing progressive loss of coordination, speech difficulty, and abnormal eye movements. Their findings are published in the July 27, 2009 issue of Journal of Neuroscience.
News of the day
Antivirals Might Be Wasted On The Elderly, Researchers Warn
A model of influenza transmission and treatment suggests that, if the current swine flu pandemic behaves like the 1918 flu, antiviral treatment should be reserved for the young. Researchers writing in the open access journal BMC Infectious Diseases found that, in this situation, providing the elderly with antiviral drugs would not significantly reduce mortality, and may lead to an increase in resistance.
Cardiovascular

In A Chemical Library, Yale Researchers Find Keys To Cell Movement

Rummaging through a biotechnology company"s chemical closet, Yale University researchers found two molecules that will allow scientists to better study how cells move. The study in the journal Nature, published online Aug. 2, describes how two small molecules discovered by Cytokinetics Inc. block the action of a key complex that directs the assembly of actin filaments, which produce the force to help cells move. The target of these inhibitors is the Arp2/3 complex, a cellular component so vital that cells die without it. This dependence has made it challenging to learn exactly which cellular processes depend upon the complex. Thomas Pollard, senior author the study and Sterling Professor of Molecular, Cellular & Developmental Biology, said that the inhibitors will allow scientists to turn the complex off and on, helping shed light on the mechanism of cell movement. Pollard noted that cell biologists "desperately need these tools to switch Arp2/3 complex off reversibly without killing the cells." These inhibitors should help scientists determine how nerve cells grow processes to wire the nervous system, embryonic cells migrate to form organs and white blood cells find bacteria. Although the molecules were not useful to Cytokinetics as drug candidates, they are of great scientific interest to biological researchers who study the movement of cells. Pollard"s team determined the crystal structures showing where both of the molecules lodge to block the action of Arp2/3 complex. Pollard serves on the Scientific Advisory Board of Cytokinetics, which found the inhibitors and collaborated on the project. Other Yale authors on the paper include Bradley Nolen, the co-lead author, and CD McCormick. Cytokinetics Inc. and the National Institutes of Health funded the study. Link: Thomas D. Pollard Yale University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):